JLE

e-VEGF-IMMUNO-actu

MENU

Essai OLIVIA : quadrithérapie avec bévacizumab Volume 11, numéro 1, Janvier 2016

  • [1] Falcone A, Ricci S, Brunetti I. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer : the Gruppo Oncologico Nord Ovest. J Clin Oncol. 2007;25:1670-6.
  • [2] Loupakis F, Cremolini C, Masi G. Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer. N Engl J Med. 2014;371:1609-18.
  • [3] Cremolini C, Loupakis F, Antoniotti C. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer : updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. Lancet Oncol. 2015;16:1306-15.
  • [4] Gruenberger T, Bridgewater J, Chau I. Bevacizumab plus mFOLFOX-6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer : the OLIVIA multinational randomised phase II trial. Ann Oncol. 2015;26:702-8.
  • [5] Ye LC, Liu TS, Ren L. Randomized controlled trial of cetuximab plus chemotherapy for patients with KRAS wild-type unresectable colorectal liver-limited metastases. J Clin Oncol. 2013;31:1931-8.
  • [6] Heinemann V, von Weikersthal LF, Decker T. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3) : a randomised, open-label, phase 3 trial. Lancet Oncol. 2014;15:1065-75.
  • [7] Lenz H, Niedzwiecki D, Innocenti F. CALGB/SWOG 80405 : phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with expanded ras analyses untreated metastatic adenocarcinoma of the colon or rectum (mCRC). ESMO. 2014;A501O.
  • [8] Ychou M, Rivoire M, Thezenas S. A randomized phase II trial of three intensified chemotherapy regimens in first-line treatment of colorectal cancer patients with initially unresectable or not optimally resectable liver metastases. The METHEP trial. Ann Surg Oncol. 2013;20:4289-97.
  • [9] Folprecht G, Gruenberger T, Bechstein WO. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab : the CELIM randomised phase 2 trial. Lancet Oncol. 2010;11:38-47.
  • [10] Folprecht G, Gruenberger T, Bechstein W. Survival of patients with initially unresectable colorectal liver metastases treated with FOLFOX/cetuximab or FOLFIRI/cetuximab in a multidisciplinary concept (CELIM study). Ann Oncol. 2014;25:1018-25.
  • [11] Wong R, Cunningham D, Barbachano Y. A multicentre study of capecitabine, oxaliplatin plus bevacizumab as perioperative treatment of patients with poor-risk colorectal liver-only metastases not selected for upfront resection. Ann Oncol. 2011;22:2042-8.